| Assessment Status |
Rapid Review Complete |
| HTA ID |
20040 |
| Drug |
Imipenem/cilastatin/relebactam |
| Brand |
Recarbrio® |
| Indication |
For the treatment of infections due to aerobic gram-negative organisms in adults with limited treatment options. |
| Rapid review commissioned |
31/08/2020 |
| Rapid review completed |
21/10/2020 |
| Rapid review outcome |
A full HTA is recommended to assess the clinical effectiveness and cost effectiveness of imipenem/cilastatin/relebactam compared with the current standard of care, on the basis of the proposed price relative to currently available therapies. |
